Martin Renatus, Chemical Biology Therapeutics
Martin Renatus, Chemical Biology Therapeutics

Lutz Hegemann, M.D., Ph.D.

Group Head of Corporate Affairs and Global Health

Lutz Hegemann, M.D., Ph.D.

Group Head of Corporate Affairs and Global Health

Martin Renatus, Chemical Biology Therapeutics

Nationality: German | Year of birth: 1966

As Group Head of Corporate Affairs and Global Health, Lutz Hegemann is responsible for driving forward the corporate strategy of Novartis and integrating global health and environmental, social and governance (ESG) matters into the core of the business.

In this newly created role, Lutz leads three teams: the Corporate Strategy function, which oversees the execution of the Novartis strategy; the ESG Management Office, which integrates ESG activities across the company; and the Global Health organization, which focuses on transforming health in low- and middle-income countries, with flagship programs targeting malaria, leprosy, sickle cell disease and Chagas disease.

Combining these teams into a single unit ensures a co-ordinated approach to maximize our contribution to society and ensure as many patients as possible have access to our treatments. We are building a strong foundation for the next phase of our global health and ESG journey.

Before taking on his present role in February 2021, Lutz was Chief Operating Officer for Global Health at Novartis. He has held roles of increasing responsibility since joining the company in 2005 in the Consumer Health Division. He began his career as a public health physician and scientist.

Lutz is a Fellow of the Royal Society for Tropical Medicine & Hygiene and serves on the boards of the Novartis Foundation, the Swiss Alliance against Neglected Tropical Diseases, the Tanzania Training Centre of International Health, and PATH.

Information is accurate as of July 5, 2021